Albumin binding of bumetanide

Area of Science:

• Pharmacology
• Biochemistry

Background:

• Human serum albumin (HSA) is a primary binding protein for many drugs and endogenous compounds.
• Understanding drug-protein interactions is crucial for predicting drug efficacy and toxicity.

Purpose of the Study:

• To investigate the binding of bumetanide to human serum albumin.
• To determine if bumetanide competes with bilirubin or diazepam for HSA binding sites.
• To assess the potential risk of bumetanide affecting bilirubin-albumin binding in newborns.

Main Methods:

• Ultrafiltration was used to study bumetanide-HSA binding and determine the stoichiometric binding constant.
• The peroxidase method and a dialysis rate method were employed to assess bumetanide's displacement of bilirubin and diazepam from HSA.
• Experiments utilized both purified HSA and pooled human serum (umbilical cord and adult).

Main Results:

• The stoichiometric binding constant for bumetanide to HSA was determined to be 6.4 x 10^4 M^-1.
• Bumetanide demonstrated competitive binding with bilirubin, with a displacement constant (KDispl) of 6.2 x 10^3 M^-1.
• This bilirubin displacement effect was confirmed in both umbilical cord and adult serum.
• Bumetanide showed lesser competition with diazepam binding to HSA, with no observed competition in pooled sera.

Conclusions:

• Pharmacological concentrations of bumetanide are unlikely to significantly alter bilirubin-albumin binding.
• The study suggests that bumetanide use should not increase the risk of bilirubin encephalopathy in newborn infants.